Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) dropped 2.4% during mid-day trading on Wednesday . The stock traded as low as $13.31 and last traded at $13.54. Approximately 232,394 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 850,806 shares. The stock had previously closed at $13.88.
Wall Street Analyst Weigh In
NAGE has been the subject of several research analyst reports. Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Saturday, June 14th. Canaccord Genuity Group raised their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Finally, Roth Capital reiterated a "buy" rating and set a $23.00 price target (up previously from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th.
Check Out Our Latest Analysis on NAGE
Niagen Bioscience Stock Down 0.7%
The business's 50-day moving average price is $9.90 and its 200 day moving average price is $7.33. The company has a market capitalization of $1.09 billion, a P/E ratio of 81.06 and a beta of 2.08.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Read More
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
